Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas

Cancer Research

Volumn 61, Issue 9, 2001, Pages 3826-3836

  Ding, Hao ^a,b   Roncari, Luba ^a,b   Shannon, Patrick ^c   Wu, Xiaoli ^a   Lau, Nelson ^a,b   Karaskova, Jana ^d   Gutmann, David H ^e   Squire, Jeremy A ^d   Nagy, Andras ^a   Guha, Abhijit ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P16; PROTEIN P19; PROTEIN P21;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOMA; CARCINOGENICITY; CELL INFILTRATION; CHROMOSOME ANALYSIS; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GERM LINE; GLIOMA; HISTOPATHOLOGY; IMMUNOREACTIVITY; MITOSIS INDEX; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE; TUMOR CELL; TUMOR MODEL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALS; ASTROCYTES; ASTROCYTOMA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 0035328722     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. The new WHO classification of brain tumours
2. A tiger behind many doors: Multiple genetic pathways to malignant glioma
3. Molecular pathogenesis of malignant gliomas
4. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification
5. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
6. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
7. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
8. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
9. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome
10. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
11. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma
12. A Phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
13. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: A preclinical study
14. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells
15. Platelet-derived growth factor in human glioma
16. L. Ras oncogenes in human cancer: A review
17. Proliferation of human malignant astrocytomas is dependent on Ras activation
18. Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras
19. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3- K/AKT signaling in a neurofibromatosis I astrocytoma
20. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
21. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of antiproliferative, pro-apoptotic, and anti-angiogenic effects
22. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II - Preclinical studies in a nude mouse model
23. In vitro differentiation of embryonic stem cells into glial cells and functional neurons
24. Functional studies in cultured astrocytes
25. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
26. Multicolor spectral karyotyping of human chromosomes
27. Multiple Ras functions can contribute to mammalian cell transformation
28. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
29. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
30. Conditional genome alteration in mice
31. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice
32. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
33. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects
34. Creation of human tumour cells with defined genetic elements
35. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
36. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
37. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle
38. Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4
39. 1 cell-cycle arrest pathways to induce glioma-like lesions in mice
40. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
41. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
42. CDKN2 (p16/ MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
43. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets
44. Tumor spectrum in ARF-deficient mice